A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : OS / oseltamivir

[Related PubMed/MEDLINE]
Total Number of Papers: 12
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   OS  (>> Co-occurring Abbreviation)
Long Form:   oseltamivir
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs. FC, hCE1, RS
2018 Combined efficacy of oseltamivir, isoprinosine and ellagic acid in influenza A(H3N2)-infected mice. EA, GR, IP, MST, PI, ROS, SOD, TBARS
2018 Preparation and Evaluation of Oseltamivir Molecularly Imprinted Polymer Silica Gel as Liquid Chromatography Stationary Phase. MIP
2017 Fate of new three anti-influenza drugs and one prodrug in the water environment. AMN, FAV, LAN, LANO, OC, PER, ZAN
2016 In vitro and in vivo stability of oseltamivir within a bioequivalence trial. HPLC, OSC
2015 Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. V/F
2015 Prediction, risk and control of anti-influenza drugs in the Yodo River Basin, Japan during seasonal and pandemic influenza using the transmission model for infectious disease. OC, ZAN
2013 Chemical probes for drug-resistance assessment by binding competition (RABC): oseltamivir susceptibility evaluation. RABC
2013 Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: improved applicability to pharmacokinetic study. OSC
10  2011 Optimization of polymerization parameters for the sorption of oseltamivir onto molecularly imprinted polymers. 4-VP, AA, EGDMA, MIPs
11  2011 Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. BALF, p.i
12  2011 Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. AUC, CyA, PK, TAC